Full text is available at the source.
Abstract
Weight losses of up to 22.5 kg have been observed with the GLP-1/GIP receptor coagonist tirzepatide after 72 weeks.
- Obesity is recognized as a chronic disease, with BMI as a target for reducing associated complications.
- A stepwise treatment approach for obesity includes lifestyle changes, pharmacological options, and surgical interventions.
- Incretin-based medications, like GLP-1 and GIP receptor activators, enhance satiety and improve the effectiveness of obesity treatments.
- Trial data shows liraglutide leads to an average weight loss of 7.5 kg after 160 weeks, while semaglutide results in up to 17.4 kg after 68 weeks.
- Tirzepatide achieves weight loss of up to 22.5 kg after 72 weeks, approaching the effects seen with bariatric surgery.
- Semaglutide has also shown beneficial outcomes in cardiovascular trials.
Simplified